Cargando…
P740: PK, PD AND SAFETY OF FIRST-IN-HUMAN, FIRST-IN-CLASS PHASE I TRIAL (AUR103-101; BHARAT) OF AUR103, AN ORAL CD47 INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES
Autores principales: | Krishnappa, Manjunath, Mandavia, Divyesh, Jain, Minish, S, Mukesh, Patel, Ankit, Agarwal, Anshul, Giri, Sanjeev, Kumar Tiwari, Nirbhay, Thiyagarajan, Saravanan, Dey, Mamon, Padmanabha Naidu, Gutta, Ramachandra, Murali, Kumar, Akhil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429211/ http://dx.doi.org/10.1097/01.HS9.0000969864.18372.7f |
Ejemplares similares
-
Aur. Cor. Celsus on Medicine
Publicado: (1837) -
Swasthya Aur Rog. (Health and Disease)
Publicado: (1933) -
M. Charcot on Menière's Disease, or Vertigo ab Aure Læsâ
Publicado: (1874) -
Brazilian Urologist's mental health aspects auring the Covid-19 pandemic
por: da Silva, Aline Gularte Teixeira, et al.
Publicado: (2020) -
1014. Decreasing Antimicrobial Use by 25% via Submission to NHSN-AUR Module
por: Kassamali, Zahra, et al.
Publicado: (2019)